المؤلفون: Novello M; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Stocchi L; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Steele SR; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Holubar SD; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Duraes LC; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Kessler H; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Shawki S; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA., Hull LT; Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.

المصدر: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Feb 10; Vol. 14 (2), pp. 185-191.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN: 1876-4479 (Electronic) Linking ISSN: 18739946 NLM ISO Abbreviation: J Crohns Colitis Subsets: MEDLINE

مواضيع طبية MeSH: Adalimumab/*therapeutic use , Antibodies, Monoclonal, Humanized/*therapeutic use , Gastrointestinal Agents/*therapeutic use , Inflammatory Bowel Diseases/*surgery , Infliximab/*therapeutic use, Case-Control Studies ; Combined Modality Therapy ; Female ; Humans ; Inflammatory Bowel Diseases/drug therapy ; Male ; Postoperative Complications/epidemiology ; Prospective Studies ; Surgical Wound Infection/epidemiology ; Treatment Outcome